IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC O 6 2006

In re application of: Gwong-Jen J. Chang

Application No. 09/826,115

Filed: April 4, 2001 Confirmation No. 4134

NUCLEIC ACID VACCINES FOR For:

PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin, Ph.D.

Art Unit: 1648

Attorney Reference No. 6395-64908-01

MAIL STOP AF COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AF, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed November 30.



TRANSMITTAL LETTER

Submitted herewith for filing in the application referenced above are the following:

- Copy of Office communication dated September 27, 2006 (8 pages)
 - Communication to the Examiner (1 page)
 - Exhibit A including:
 - Copy of Information Disclosure Statement submitted July 27, 2001 (2 pages)
 - Copy of Form 1449 (4 pages)
 - Copy of Return Postcard from PTO acknowledging receipt (1 page)
 - Exhibit B including:
 - Copy of Information Disclosure Statement submitted February 15, 2002 (2 pages)
 - Copy of Form 1449 (2 pages)
 - Copy of Return Postcard from PTO acknowledging receipt (1 page)
- 冈 Please update PTO records to reflect Attorney Reference No. 6395-64908-01.
- \boxtimes The Director is hereby authorized to charge any additional fees that may be required, or credit overpayment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- 冈 Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Docketing

Gwynedd/Warren, Ph.D. Registration No. 45,200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Gwong-Jen J. Chang **Application No. 09/826,115**

Filed: April 4, 2001

Confirmation No. 4134

For:

DEC 0 6 2006

NUCLEIC ACID VACCINES FOR

PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin, Ph.D.

Art Unit: 1648

Attorney Reference No. 6395-64908-01

MAIL STOP AF COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AF, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed November 30, 2006

COMMUNICATION TO THE EXAMINER

Enclosed as Exhibit A are copies of an Information Disclosure Statement ("IDS") and 1449 Form previously submitted in this application to the U.S. Patent and Trademark Office ("PTO") on July 27, 2001. Also enclosed as part of Exhibit A is a copy of the return postcard dated July 30, 2001, acknowledging receipt by the PTO of the IDS, 1449 Form, and accompanying paper copies of the references.

Enclosed as Exhibit B are copies of an IDS and 1449 Form previously submitted in this application to the PTO on February 15, 2002. Also enclosed as part of Exhibit B is a copy of the return postcard dated March 1, 2002, acknowledging receipt by the PTO of the IDS, 1449 Form, and accompanying paper copies of the references.

As a courtesy to the Examiner, a copy of this filing is being provided directly via facsimile number (571) 273-0908.

These documents are being submitted as evidence of the proper submission and receipt by the Patent and Trademark Office of the cited references. Copies of the cited references are available in electronic form in the related U.S. Patent Application No. 10/500,796. Applicants respectfully request consideration of the documents properly cited during prosecution of this application, and that these documents be listed as references cited on the issued patent.

> Respectfully submitted, KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Gwynedd Warren, Ph.D. Registration No. 45,200



United States Patent and Trademark Office

ONITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|----------------------------|-----------------|----------------------|-------------------------|------------------|
| 09/826,115 | 04/04/2001 | Gwong-Jen J. Chang | 14114.0332Ų3 | 4134 |
| 46135 | 7590 09/27/2006 | PE | EXAM | INER |
| | T SPARKMAN, LLP | O. 40. | PARKIN, JI | effrey s |
| 121 S.W. SAL SUITE 1600 | MON STREET | | ART UNIT | PAPER NUMBER |
| PORTLAND, | OR 97204 | DEC 0 6 2006 | 1648 | - |
| • | | PADEMAN, | DATE MAILED: 09/27/2000 | |

Please find below and/or attached an Office communication concerning this application or proceeding.



U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

COMMISSIONER FOR PATENT P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO J FILING DATE FIRST NAMED INVENTOR / ATTORNEY DOCKET NO.

CONTROL NO. PATENT IN REEXAMINATION



EXAMINER

ART UNIT PAPER

09202006

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The information disclosure statements (IDSs) (dated 27 July, 2001, and 15 February, 2002) that accompanied the communication dated 03 February, 2006, fail to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. Applicants state that these IDSs were provided earlier, however, no such electronic record of these documents is present. Additionally, none of the cited references were present in the electronic application. Applicants are invited to resubmit these IDSs along with the proper mailing documentation. Legible copies of each reference should also be provided pursuant to 37 CFR 1.98(a)(2). Applicants should clearly identify any documents that were submitted in an earlier filed copending application if they are not providing additional copies.

Jeffrey S. Parkin, Ph.D. Primary Examiner Art Unit: 1648

ATYGRMEY DOCKET NO. 14114.0332/3 SERIAL NO. 09/826,113 Page 1 of 4

COPY

| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7- | | | | ATTORNEY DOCKET NO.: 14114.033203 SERIAL NO. 09/826,115 | | | |
|---|---|--------------------------------|----------------------------|---|---------------------------|--------------------------|----------------------------------|
| 80) | | EMARK OFFICE | . [| APPLICANT: Chang | | | |
| LIST OF (Use s | LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | FILING DATE: April 4, 2001 | | | Insertaned 1648 |
| | | - | ··· | U.S. PATENT DOCUMENTS | | | |
| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLAS S | FILING CATE IP APPROPRIATE |
| | AA, | 5,514,375 | 03/07/96 | Puoletti et al. | 121 | 199.1 | |
| | \\\ ₈ / | 5,494,671 | 02/27/96 | boi et al. | 424 | 218.1 | |
| | * | 5,229,293 | 07/20/93 | Motodura et al | 435 | 320.1 | ļ |
| | A | 5,021,347 | 08/04/91 | Yosui et al. | 435 | 235 | |
| | VE) | 4,810,492 | 03/07/89 | Fujita et al. | 424 | 88 | |
| | | | | | <u> </u> | | |
| | | | | FOREIGN PATENT DOCUMENTS | | | |
| | AF | WO 99.163095 | 12/09/98 | PCT | | | |
| | J.G. | WO 93/06214 | 04701/93 | PCT | | <u> </u> | |
| | Å | WO 92/03545 | 03/05/92 | PCT | ļ | <u> </u> | |
| | AI | WO 50/01946 | 03/08/90 | PCT | ļ | | |
| | | | | | | | |
| | | OTHER PRIC | R ART (Inc. | inding Author, Title, Date, Pertiner | it Pages, E | te.) | |
| | TA / | preparation, integrated re- | useful as v combinant v | t Publication No. JF 03276941 "Non- accine - by infecting preliminary 2 accinia virus, and then separating flavivirus," (October 26, 1993) | lavivirus | infected c | oll With cona |
| | AN | Daubel et Al. | , Rucleotid | e Sequence and Deduced Amino Acid S 2 Virus, Jamaica Genotype: Comparat | equence of ive Analys | the Wonst | ructural Full-Length |
| | ¥ | Challenge and | Expresses . | e virus Recombinant UNA Vaccine Pr in Vitro a Nobinfectious Recombinant ays. J. Virol. 75(9): 4086-4047 (200 | Antigen T | hat Can Be | Used in Easyme- |
| | Konishi et al., Generation and Characterization of a Nammalian Cell Line Continuously Expressing Japanese Encephalitis Virdo Subviral Particles. J. Virol. 75(5): 2204-2212 (2001) | | | | | | uously 4-2212 (2001) |
| | Ad | Asnis et al., Experience. C | The Wost I | Hile Virus Outbreak of 1999 in New Y | OZEL THE | Clushing Ho | ospital |
| | Ad | Chang et al., Immunity and | A Single 1 Prevente Ja | Intramuscular Injection of Recombina panese Encephalitis in Mice. J. VI. | nt Plasmic rol. 74(9): | 1 DHA Loduc 4244-4252 | Protective |
| | AP | Garmendia et | al., Recov | ery and Identification of West Nile 3110-3111 (2000) | Virus from | a a Rawk i | Winter. |

PAGE 15/18 * RCVD AT 2/3/2005 6:31:33 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:228 9445 * DURATION (mm-ss):05-00

ATTORNEY DOCKET NO. 14114.0332U3 SERIAL NO. 09/826,115 Pogo 2 of 4

COPY

| AC | Johnson et al., Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay, J. Clin. Microbiol. 38(5): 1827-1831 (2000) |
|------------|--|
| 14 | Martin et al., Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Asayaya for Routine Diagnosis of Arboviral Infections. J. Clin. Microbiol. 38(5): 1823-1826 (2006) |
| Aŝ | Update: Eurveillance for West Nile Virus in Overwintering Mosquitos New York, 2008. Marb. Mortal. Whly. Rep. 49(09): 178-179 (Mar. 10, 2000) |
| 142 | Update: West Nile Virus Activity Northeastern United States, 2000. Horb. Mortal. Wkly. Rep. 49(36): 820-822 (Sept. 15, 2000) |
| Αυ | Aberle et al., A DNA Immunization Model Study with Constructs Expressing the Fick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms. J. Immunod. 163: 6756-6761 (1899) |
| Įν | Anderson et al., Isolation of West Hilu Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut. Science 28: 2331-2333 (Dec. 17, 1999) |
| VM. | Azevedo et al., Main features of DNA-based immunization vectors. Bred. J. Med. Biol. Res. 32(2): 147-153 (1999) |
| × | Jia et al., Genetic analysis of West Nile New York 1999 encephalatic virus. Lancet 354: 1971-1972 (Dec. 4, 1999) |
| ¥ | Lanciotti et al., Origin of the most Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States. Science 286: 2333-2337 (Dec. 17, 1999) |
| 1 | Mir et al., High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Nat. Acad. Sci. USA 96: 4262-4260 (1999) |
| | Ho et al. DNA vaccination induces a long-term antibody response and protective immunity against pseudorables virus in mice. Arch. Virol. 143: 115-125 (1998) |
| jab jab | Konishi et al., Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes. J. Virol. 72(6):4925-4930 (June 1998) |
| B¢ | Kuno et al., Phylogeny of the Genus Flavisirus. Nicol. 72(1): 73-83 (Jan. 1998) |
| ВО | Lin et al., DNA Immunisation with Japanese Encephalitis Virus Bonstructural Protein H81 Elicits Protective Immunity in Nicc. D. Virol. 72(1): 191-200 (Jan 1988) |
| BE | Klinman et al., CpG motifs as immyde adjuvants. Vaccine 17: 19-25 (1999) |
| 85 | Rochel et al. Inoculation of plasmids expressing the dengue 2 envelope gene elicit neutralizing antibodies in mige. Vaccine 15(5): 547-552 (199 N |
| BG | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |
| Вн | Dmitriev et al., Immunization with recombinant vaccinis viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus con protect mice against lethal encephalitis. J. Biotechnol. 44: 97-103 (1996) |
| ВІ | Hennessy et al., Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347: 1583-1586 (1996) |
| вз | thillpotts et al., Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch. Virol. 141: 743-749 (1996) |
| ВИ | |
| BI | Allicon et al., Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form. J. Virol. 69(9): 5816-5820 [Sept 1995] |
| Br | Chen et al., Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mica. J. Virol. 69(8): 5186-5190 (Aug 1993) |

ATTORNEY DOCKET NO. 14114.0332U3 SERIAL NO. 09/826,115 Page 3 of 4

COPY

| - 1 | BN | dos Santos et al:, Complete nucleotide sequence of yellow fever virus vaccing strains 170p and 170-213. Virus Research 35: 15-41 (1995) |
|-----|----|--|
| | во | Ventgopal et al., Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. Vaccine 13(11): 1000-1005 |
| | BF | Mandl et 1., Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elementa in Tick-Borne Versus Mosquito-Borne Flaviviruses. Virology 194: 173-184 (1993) |
| | 80 | Konishi et al., Mice Immunized with a Subviral Particle Containing the Japanese Encephalicia Virus prM/M and E Proteins Are Protected from Lethal JEV Infection. Virology 188: 714-720 (1992) |
| | BR | Molff et al., Long term persistence of plasmid DNA and foreign gene expression in mouse muscle, Num. Mol. Gaget. 1(6): 363-369 (Sept. 1992) |
| | BŞ | Konishi et al., Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or MSA of Japanese Encephalitis Virus. Virology 185, 401-410 (1991) |
| · | BŦ | Mason et al., Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection. Virology 180: 294 305 (1991) |
| | BŲ | Palgout et al., Immunization of Mice with Recombinent Vaccinia Virus Expressing Authentic Dongue Virus Nonstructural Protein NS1 Protects Against Lettal Dengue Virus Encephalitia. J. Virol. 64(9): 4356-4363 (1990) |
| | 87 | Hitayaphan et al., Nucleotido Sequence of the Virulent SA/14 Strain of Japanese Encephalitia Virus and Ita Attenuated Vaccine Derivative, SA-14-14-2./Virology 177: 541-552 (1990) |
| | BW | Osetomi and Sumiyoshi, Complete Nucleolide Sequence of Dengue Type 3 Virus Genome RNA. Virology 176:643-647 (1990) |
| | B | Bray et al., Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephalitis. J. Virol. 63(6): 2857-2856 (1989) |
| | в | Falgout et al., Proper Processing of Dengue Wirts Nonstructural Glycoprotein MS1 Requires the N-terminal Hydrophobic Signs! Sequence and the Davistream Nonstructural Protein MS2a. J. Virol. 63(5): 1852-1860 (1989) |
| | BZ | Rochrig et al., Synthetic Feptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephylitis Virus Elecit Antiviral Antibody. Virology 171: 49-60 (1989) |
| | 4 | Zhang et al., Passive Protection of Mice, Goate, and Monkeys Against Japanese Encephalitis With Moncelonal Antibodies. J. Mpd. Virol. 29: 133-138 (1981) |
| | da | Hahn et al. Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses / Virology 162: 167-180 (1988) |
| | cc | of the Course of Tongon of Tongon of Tongon |
| | Po | Osatomi et al., Nucleotide Sequence of Dengue Type 3 Virus Genomic RMA Encoding Viral Structural Proteins. Virus Genes 2(1): 99-108 (1988) |
| | 4 | Thang et al., Indunization of Mice with Dengue Structural Proteins and Nonscructural Protein NS1 Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Excephalitis. J. Virol. 62(8): 3027-3031(1988) |
| | CF | The state of Cases Police for |
| | CG | Total State of the |
| | CH | Front et al., Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Protoins, NS1, ns2a, and ns2b. Virology 156; 293-304 (1987) |

ATTORNEY DOCKET NO. 14114.0332/3 SERIAL NO. 09/826,115 Page 4 of 4

COPY

| | \q_ | Thao et al., Expression of Dengue Virus Structural Proteins and Nonstructural Protein MS by a Recombinant Vaccinia Virus. J. Virol. 6)(12): 4019-4022 (1987) |
|----------|---------|--|
| | ÇJ | Deubel of al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Struckdral Proteins of Dengue Type 2 Virus, Jamaica Genotype. Virology 155: 365-377 (1986) |
| | СK | Kimura-Kuroda et al., Antigenic Comparison of Envelope Protein B between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies. J. Gan. Virol. 67: 2663-2672 (1986) |
| | CL | Zhao et al., Cloning Full-Length Bengue Type 4 Viral DMA Sequences: Analysis of Genes Coding for Structural Proteins. Virology 155: 77-88 (1986) |
| - | СН | Rice et al., Nucleotide Sequence of Yellow Reyer Virus: Implications for Flavivirus Gene Expression and Evolution. Science 229: 216-733 (1985) |
| | CN | Seeger et al., The cloned genome of ground squirrel Repatitie virus is infectious in the animal. Proc. Natl. Acad. Sci. USA 81(18): 5849-5852 (Sep 1984) |
| - | co | Kimura-Kuroda et al. Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 LBT of Japanese Encephalitis Virus, Using Monoclonal Antibodies. J. Virol. 45(1): 124-132 (1983) |
| | CP | Rochrid et al., Identification of Epitopes on the E Glycoprotein of Saint Douis Encephalitis Virus Using Monoclonal Antibodies. Virology 128: 118-126 (1983) |
| | GO. | Hunt and Calisher, Relationships of Bunyamuera Group Viruses by Neutralization. Amer. of frop. Med. Hvg. 28(4): 740-749 (1979) |
| ехлитиен | : , | DATE CONSIDERED: 04 20 06 |
| | citatio | ial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line on if not in conformance and not considered. Include copy of this form with next communication |

Referencer account considered because the IDS Bails to corplying CFR. 1917 and 1.28.

ATTORNEY DOCKET NO. 14114.033213 SERIAL NO. 09/826,115 Page 1 of 2

COPY

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7- | | | sev. 7- | ATTORNEY DOCKET NO.: 14114.033203 SERIAL BO. 09/826,115 | | | |
|---|---|--|------------------------------|--|----------------------------------|--------------------------------|----------------------------------|
| ROY | | MARK OPFICE | | APPLICANT: Cheng | | | |
| LIST OF | PRIOR . | ART CATED BY A | PPLICANT SEATY) | FILING DATE: April 4, 2001 | | GROUP : | Unappigned 1644 |
| | | | | U.S. PATEUR DOCUMENTS | | | · |
| EXAMINER INITIAL | | DOCUMENT NO. | DATE | name | CLASS | SUBCLASS | PILING DATE IP APPROPRIATE |
| | X | -6,365,417 · | 12/26/00 | 10y at ai. | ļ | | |
| | | | | | J | | |
| | | | | POREIGN PATENT DOCUMENTS | | 1 | |
| | | | | | | | |
| | | | | luding Author, Title, Date, Pertis | ADT PAGES | Pto-) | |
| | | | | Study of Recombinant Adenovirus Vec | | | |
| | 82 | 2 Sinole-Chair | i (sPv) Antil | body Gene for Previously Treated Ov . 8:229-242 (January 20, 1997) | arian and D | (traovarian (| Cancer |
| | 93 | Selay. The Ch Boca Reton, P | L. pp 63-9 | rier. Synchetic Vaccines Volume I 2 (1987) | (edited by | Arnon) ORC | Press Inc., |
| | B4 | Clorke et al. Borne Viruses | Techniques . Amer. J. | For Hemagglutination And Hemaggl Trop, Med. and Ryg. 7:561-573 (19 | utination-Z | nhibition wi | ith Arthropod- |
| | a 5 | Gruenborg et Structural Pr 69:1391-1398 | oteins of D | Nucleobide Sequence and Deduced ongue Virus Type 2, New Guinea C | Ameno Acid and POO-218 | Boquence of Strains. J. | the . Gen. Virol. |
| | 24 | Heinz et al. Vaccines (edi 289-305 (1990 | Plaviviruse ted by von | s. Immunochemistry of Vipuses II: Regenmortel and Neural Elsevier | The Basis Science Pu | for Serodies blishers.Ch | gnosis and apter 14, pp. |
| | ŧ, | Menchal et el Antibodies By | . Dengue Vir Indirect Im | us-Specific And Plavivirus Group De munofluorespense, Amer. J. Trop. Mc | terminants : | Ideactified Wi 30-836 (198) | ith Momorlenal |
| | В | hubálak et al. Dis. 5(5):643 | . West Nile 1 -610 (1999) | Pever-a Resmarying Mosquito-Borna V | iral Disease | e in Europe. | Bookg. Infect. |
| | Robler et al. Continuous cultures of fused cells secreting entibody of prodefined specificity. Nature 256:495-497 [August 7, 1975] | | | | | | |
| · | 312 | Konishi et al candidates An | Avipox vi combination | rus-vectored Japanese encephaliti n with purified subunit immunogen | s virus vac s. <i>Vaccine</i> | cines: 000 (12(7):633-6 | as vaccine 38 (1994) |
| | B11 | Eugaryotic El | NAs. Hol. C | Mechanisms of Inhibition of Tran coll. Biol. 9(11):5134-5142 (Novem | ber 1989) | | |
| | B12 | Lagrandi. Clear Nature 277:68 | vage of Stru 0-685 [Augus | ctural Proteins during the Assembly t 15, 1970] | of the Head | i of Bacteri | ophage f4. |

ATTORNEY DOCKET NO. 14114.03321/3 \$ER(AL NO. 09/826.115 Page 2 of 2

COPY

| | B13 | Lai et al. Immunization of Monkeys with Raculovirus Recombinant-expressed Dengue Envelope and Not Glycoproteins Induces Partial Resistance to Challonge with Komotypic Dengue Virus. In Vaccines 90; Modern Approaches to New Vaccines including Prevention of AIns. Cold Spring Merbor Laboratory. Cold Springs Resbur, NY pp. 119-124 (1990) |
|-------------------------------|-------------|--|
| | Bla | Nason et al. Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NSi. Virology 161:262-267 (1987) |
| | P 15 | Smithburn et al. A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda. Am. J. Trop. Med. Hyg. 20:471-492 (2940) |
| | A16 | Tardei et el. Evaluation of Immunoglobulin y (IgK) and IgG Empine Immunoassays in Serologic Diognosis of West Nile Virus Infection J. Clin. Hicrobiol. 38(6) 8232-2239 (June 2000) |
| | В.7 | Tssi of el. Japanese Encephalitis Vaccinos. In Vaccines, (3rd edition) (edited by Plotkin and Orenstein), W.S. Saundors Company, Philadelphia, PA. Chapter 27, pp. 672-710 (1994) |
| | B18 | Tool et al. Japanese Encephalitis Vaccines. In Vaccines, (2rd edition) (edited by Plotkin and Morcimer). W.B. Saunders Co., Philadelphis, PA. Chapter 24, pp. 671-713 (1994) |
| | 919 | Yang et al. A p300/CEP-associated factor that competes with the adenoviral encoprotein Eia. Nature 192:319-324 (July 25, 1996) |
| | | |
| EXAMINE | Ri A | DATE CONSIDERED: 09/20/06 |
| EXAMINE through to appl | citatio | ial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line a if not in conformance and not considered. Include copy of this form with next communication |

* reference were not considered because the IDS failete couply with 37 CF. N. 1,97 + 1,98.



ATTORNEY DOCKET NO. 14114.0332U3 PATENT

Examiner: Unassigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Chang

Serial No.: 09/826,115

Filed: April 4, 2001

For:

NUCLEIC ACID VACCINES FOR

PREVENTION OF FLAVIVIRUS INFECTION

Group Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

July 27, 2001

Sir:

Submitted herewith on form PTO 1449 is a listing of documents known to applicants and/or their attorneys in compliance with the requirements of 37 C.F.R. § 1.56. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Applicants believe that this Information Disclosure Statement is being filed in accordance with 37 C.F.R. § 1.97(b)(3), i.e., before the mailing date of the first Office Action on the merits pertaining to the above-referenced application. Therefore, no fee is believed to be due. However, if a fee is



ATTORNEY DOCKET NO. 14114.0332U3 Serial No. 09/826,115

required, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Registration No. 39,303

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811 404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Mary L. Miller

Dat

| | | OF COMMERCE (R | ev. 7- | ATTORNEY DOCKET NO.: 14114.0332U3 | | SERIAL NO | 0. 09/826,115 |
|---------------------------------|--|-----------------------------------|----------------------------|--|--------------|--------------|----------------------------------|
| 80) PATENT AND TRADEMARK OFFICE | | | | APPLICANT: Chang | | | |
| | LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | FILING DATE: April 4, 2001 | | GROUP: | Jnassigned |
| | , | | | U.S. PATENT DOCUMENTS | | | |
| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLAS S | FILING DATE IF APPROPRIATE |
| | AA | 5,514,375 | 05/07/96 | Paoletti et al. | 424 | 199.1 | |
| | АВ | 5,494,671 | 02/27/96 | Lai et al. | 424 | 218.1 | |
| · | AC | 5,229,293 | 07/20/93 | Matsuura et al. | 435 | 320.1 | |
| | AD | 5,021,347 | 06/04/91 | Yasui et al. | 435 | 235 | |
| | —AE | 4,810,492 | -03/07/89 | Fujita et al. | -424 | 88 | |
| , | | | | | | | |
| | | | | FOREIGN PATENT DOCUMENTS | | | |
| | AF | WO 99/63095 | 12/09/99 | PCT | | | |
| | AG | WO 93/06214 | 04/01/93 | PCT | | | |
| | АН | WO 92/03545 | 03/05/92 | PCT | | | |
| | AI | WO 90/01946 | 03/08/90 | PCT . | | | |
| | | • | | | | | |
| | | OTHER PRIO | R ART (Incl | uding Author, Title, Date, Pertinen | t Pages, E | tc.) | |
| | AJ | preparation, u integrated red | seful as va combinant v | t Publication No. JP 05276941 "Non-iaccine - by infecting preliminary flaccinia virus, and then separating materials of the separating of the separating materials of the separation of th | avivirus i | infected co | ell with cDNA |
| · | AK | | ngue Type | e Sequence and Deduced Amino Acid Se 2 Virus, Jamaica Genotype: Comparati 244 (1988) | | | |
| | AL | Challenge and | Expresses i | Virus Recombinant DNA Vaccine Pro n Vitro a Noninfectious Recombinant nys. J. Virol. 75(9): 4040-4047 (2001 | Antigen Th | at Can Be | Used in Enzyme- |
| | AM | | | on and Characterization of a Mammali phalitis Virus Subviral Particles. | | | |
| | AN | -Asnis-et-al.,- Experience. Cl | The West N | ile-Virus-Outbreak-of-1999 in New-Yo . <i>Dis</i> . 30: 413-418 (2000) | ork:- The -F | lushing Ho | spital |
| | . AO | | | ntramuscular Injection of Recombinar panese Encephalitis in Mice. J. Viro | | | |
| | AP | | | ry and Identification of West Nile V 3110-3111 (2000) | /irus from | a Hawk in | Winter. J. |

| | AQ | Johnson et al., Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay. <i>J. Clin. Microbiol.</i> 38(5): 1827-1831 (2000) |
|---|----|---|
| • | AR | Martin et al., Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections. <i>J. Clin. Microbiol.</i> 38(5): 1823-1826 (2000) |
| | AS | Update: Surveillance for West Nile Virus in Overwintering Mosquitos New York, 2000. Morb. _MortalWklyRep49(09): 178-179_(Mar10, 2000) |
| | AT | Update: West Nile Virus Activity Northeastern United States, 2000. Morb. Mortal. Wkly. Rep. 49(36): 820-822 (Sept. 15, 2000) |
| - | AU | Aberle et al., A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms. <i>J. Immunol</i> . 163: 6756-6761 (1999) |
| | AV | Anderson et al., Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut. <i>Science</i> 286: 2331-2333 (Dec. 17, 1999) |
| | AW | Azevedo et al., Main features of DNA-based immunization vectors. Braz. J. Med. Biol. Res. 32(2): 147-153 (1999) |
| | AX | Jia et al., Genetic analysis of West Nile New York 1999 encephalitis virus. <i>Lancet</i> 354: 1971- 1972 (Dec. 4, 1999) |
| | AY | Lanciotti et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States. Science 286: 2333-2337 (Dec. 17, 1999) |
| | AZ | Mir et al., High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Nat. Acad. Sci. USA 96: 4262-4267 (1999) |
| | ВА | Ho et al. DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice. Arch. Virol. 143: 115-125 (1998) |
| | ВВ | Konishi et al., Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes. J. Virol. 72(6):4925-4930 (June 1998) |
| | вс | Kuno et al., Phylogeny of the Genus Flavivirus. J. Virol. 72(1): 73-83 (Jan. 1998) |
| | BD | Lin et al., DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice. <i>J. Virol</i> . 72(1): 191-200 (Jan 1998) |
| | BE | Klinman et al., CpG motifs as immune adjuvants. Vaccine 17: 19-25 (1999) |
| | BF | Kochel et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. <i>Vaccine</i> 15(5): 547-552 (1997) |
| | BG | Wang et al., Immune Response to Neonatal Genetic Immunization. Virology 228: 278-284 (1997) |
| | ВН | Dmitriev et al., Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis. J. Biotechnol. 44: 97-103 (1996) |
| | BI | Hennessy et al., Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347: 1583-1586 (1996) |
| | ВЈ | Phillpotts et al., Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. <i>Arch. Virol.</i> 141: 743-749 (1996) |
| | ВК | Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization. Science 273: 352-354 (1996) |
| | BL | Allison et al., Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form. J. Virol. 69(9): 5816-5820 (Sept 1995) |
| | ВМ | Chen et al., Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice. <i>J. Virol.</i> 69(8): 5186-5190 (Aug 1995) |

| | BN | dos Santos et al., Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. <i>Virus Research</i> 35: 35-41 (1995) |
|---|----|--|
| | во | Venugopal et al., Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. <i>Vaccine</i> 13(11): 1000-1005 (1995) |
| | ВР | Mandl et al., Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses. <i>Virology</i> 194: 173-184 (1993) |
| | BQ | Konishi et al., Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection. Virology 188: 714-720 (1992) |
| - | BR | Wolff et al., Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. <i>Hum. Mol. Genet.</i> 1(6): 363-369 (Sept. 1992) |
| | BS | Konishi et al., Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus. <i>Virology</i> 185: 401-410 (1991) |
| - | вт | Mason et al., Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection. <i>Virology</i> 180: 294-305 (1991) |
| | BU | Falgout et al., Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects Against Lethal Dengue Virus Encephalitis. $J.\ Virol.$ 64(9): 4356-4363 (1990) |
| | BV | Nitayaphan et al., Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2. Virology 177: 541-552 (1990) |
| | BW | Osatomi and Sumiyoshi, Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA. Virology 176:643-647 (1990) |
| | BX | Bray et al., Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephalitis. <i>J. Virol</i> . 63(6): 2853-2856 (1989) |
| | ВУ | Falgout et al., Proper Processing of Dengue Virus Nonstructural Glycoprotein NS1 Requires the N-terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a. J . $Virol.$ 63(5): 1852-1860 (1989) |
| · | BZ | Roehrig et al., Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody. <i>Virology</i> 171: 49-60 (1989) |
| | CA | Zhang et al., Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies. <i>J. Med. Virol</i> . 29: 133-138 (1989) |
| | СВ | Hahn et al. Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses. <i>Virology</i> 162: 167-180 (1988) |
| | cc | Hashimoto et al. Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain. <i>Virus Genes</i> 1(3): 305-317 (1988) |
| | CD | Osatomi et al., Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins. <i>Virus Genes</i> 2(1): 99-108 (1988) |
| | CE | Zhang et al., Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NS1 Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis. J . $Virol.$ 62(8): 3027-3031(1988) |
| | CF | Mackow et al., The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins. <i>Virology</i> 159: 217-228 (1987) |
| | CG | Sumiyoshi et al. Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA. Virology 161: 497-510 (1987) |
| | СН | Trent et al., Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins, NS1, ns2a, and ns2b. Virology 156: 293-304 (1987) |
| | | |

| EXAMINER: | | DATE CONSIDERED: |
|-----------|----|--|
| | CQ | Hunt and Calisher, Relationships of Bunyamwera Group Viruses by Neutralization. <i>Amer. J. Trop. Med. Hyg.</i> 28(4): 740-749 (1979) |
| | CP | Roehrig et al., Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies. <i>Virology</i> 128: 118-126 (1983) |
| • | со | Kimura-Kuroda et al., Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies. <i>J. Virol.</i> 45(1): 124-132 (1983) |
| : | CN | Seeger et al., The cloned genome of ground squirrel hepatitis virus is infectious in the animal. <i>Proc. Natl. Acad. Sci. USA</i> 81(18): 5849-5852 (Sep 1984) |
| | CM | Rice et al., Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution. <i>Science</i> 229: 726-733 (1985) |
| | CL | Zhao et al., Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins. <i>Virology</i> 155: 77-88 (1986) |
| | СК | Kimura-Kuroda et al., Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies. <i>J. Gen. Virol</i> . 67: 2663-2672 (1986) |
| | СJ | Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype. <i>Virology</i> 155: 365-377 (1986) |
| | CI | Zhao et al., Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS, by Recombinant Vaccinia Virus. J. Virol. $61(12)$: $4019-4022$ (1987) |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS AND TRADEMARKS

SIR: PLEASE ACKNOWLEDGE RECEIPT OF THE ENCLOSED:

(X) Information Disclosure Statement (2 pages)

(X) Form PTO-1449 (4 pages)

(X) 69 References

(X) Certificate of Mailing: July 27, 2001

IN RE APPLICATION OF: Change

TITLE: "NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION"

SERIAL NO.:

09/826,115

FILED: April 4, 2001

REF. NO.:


14114.0332U3

(MLM/WBD:prt)

RECEIVED

AUG 0 7 2001

NEEDLE & ROSENBERG



0420

ATTORNEY DOCKET NO. 14114.0332U3 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Chang

Group Art Unit: 1642

Confirmation No. 4134

Serial No. 09/826,115

Examiner: Unassigned

Filed: April 4, 2001

For: "NUCLEIC ACID VACCINES FOR

PREVENTION OF WEST NILE VIRUS INFECTION AND NONINFECTIOUS ANTIGEN FOR DIAGNOSTIC TEST"

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT SUBMITTED IN ACCORDANCE WITH THE PROVISIONS OF 37 C.F.R. §1.97(b)

Commissioner for Patents Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

February 15, 2002

Sir:

Submitted herewith on Form PTO 1449 is a listing of documents known to applicants and/or their attorneys pursuant to the requirements of 37 C.F.R. §1.56. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.



ATTORNEY DOCKET NO. 14114.0332U3 SERIAL NO. 09/826,115

As these documents are considered to be timely filed, no fee is believed due. However, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary Miller

Registration No. 39,303

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811 404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date listed below

Mary Miller

Date

| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7- | | | | ATTORNEY DOCKET NO.: 14114.0332U3 SERIAL NO. 09/826,115 | | | D. 09/826,115 | |
|---|---------|--|------------------------------|--|-----------------------------------|------------------------------------|------------------------------|----------------------------------|
| 80) | | EMARK OFFICE | | APPLICANT: Chang | | | | |
| | | ART CITED BY A sheets if nece | | FILING DATE: April | 1, 2001 | | GROUP: [| Jnassigned |
| | | | | U.S. PATENT DOCUM | ENTS | | | |
| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | В1 | 6,165,477 | 12/26/00 | Ivy et al. | | | · | |
| | <u></u> | | | | | | | |
| | | | , | FOREIGN PATENT DOC | UMENTS | 1 | | |
| | | | | | · | | | |
| | | - Company of the Comp | | | | | | |
| | | OTHER PRIC | R ART (Incl | uding Author, Title, | Date, Pertine | nt Pages, | Etc.) | · |
| | В2 | 2 Single-Chain | (sFv) Antil | Study of Recombinant A body Gene for Previous 8:229-242 (January 2 | ly Treated Ova: | or-Mediated rian and Ex | Delivery of traovarian C | an Anti-erbB- ancer |
| | в3 | Selay. The Cho Boca Raton, Fl | pice of Carr L. pp. 83-92 | cier. Synthetic Vacc 2 (1987) | ines Volume I | (edited by | Arnon) CRC | Press Inc., |
| | в4 | | | For Hemagglutination Trop. Med. and Hyg. | | | hibition Wi | th Arthropod- |
| | в5 | Gruenberg et a Structural Pro 69:1391-1398 | teins of De | Nucleotide Sequence engue Virus Type 2, N | and Deduced Ar New Guinea C ar | mino Acid S nd PUO-218 | Sequence of Strains. J. | the Gen. Virol. |
| | В6 | Heinz <i>et al</i> . H Vaccines (edit 289-305 (1990) | ed by von I | s. Immunochemistry or Regenmortel and Neura | Viruses II: (| The Basis : Science Pul | for Serodiag olishers Cha | nosis and pter 14, pp. |
| | в7 | Henchal et al. Antibodies By | Dengue Viru Indirect Imm | s-Specific And Flaviv | irus Group Dete | erminants I . <i>Hyg</i> . 31:8 | dentified Wi 30-836 (1982 | th Monoclonal |
| · | в8 | Hubálek et al. West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe. Emerg. Infect. Dis. 5(5):643-650 (1999) | | | | | | Emerg. Infect. |
| | в9 | Kohler et al. (Nature 256:495 | | ultures of fused cell 7, 1975) | s secreting and | tibody of p | redefined sp | ecificity. |
| | в10 | Konishi et al. candidates in | Avipox vir | us-vectored Japanese with purified subur | encephalitis it immunogens. | virus vaco . <i>Vaccine</i> 1 | ines: use a 2(7):633-63 | s vaccine 8 (1994) |
| | в11 | Kozak. Circums Eucaryotic mRN | tances and As. Mol. Ce | Mechanisms of Inhibi | tion of Transl -5142 (Novembe | lation by S er 1989) | Secondary St | ructure in |
| | B12 | Laemmli. Cleava Nature 277:680- | ge of Struc 685 (August | tural Proteins during 15, 1970) | the Assembly o | of the Head | of Bacterio | phage T4. |

| | · | |
|-----------|-----|--|
| | B13 | Lai et al. Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NS1 Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus. In Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY pp. 119-124 (1990) |
| | В14 | Mason et al. Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1. Virology 161:262-267 (1987) |
| | В15 | Smithburn et al. A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda. Am. J. Trop. Med. Hyg. 20:471-492 (1940) |
| | в16 | Tardei et al. Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection. <i>J. Clin. Microbiol</i> . 38(6):2232-2239 (June 2000) |
| | B17 | Tsai et al. Japanese Encephalitis Vaccines. In <i>Vaccines</i> , (3 rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Company, Philadelphia, PA. Chapter 27, pp. 672-710 (1999) |
| | в18 | Tsai et al. Japanese Encephalitis Vaccines. In <i>Vaccines</i> , (2 nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA. Chapter 24, pp. 671-713 (1994) |
| | в19 | Yang et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein ElA. Nature 382:319-324 (July 25, 1996) |
| | | |
| EXAMINER: | | DATE CONSIDERED: |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication

to applicant.

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR: PLEASE ACKNOWLEDGE RECEIPT OF THE ENCLOSED:

X Supplemental Information Disclosure Statement (2 Pages) _X_ Form PTO-1449 (2 Pages)

X A copy of each cited reference (19 references) _X_ Certificate of U.S. Mailing dated February 15, 2002

IN THE NAME(S) OF: Chang
TITLE: "NUCLEIC ACID VACCINES FOR PREVENTION OF WEST NILE VIRUS
INFECTION AND NONINFECTIOUS ANTIGEN FOR DIAGNOSTIC TEST"
APPLN. SERIAL NO. 09/826,115 FILING DATE: APRIL 4, 2001
ATTORNEY DOCKET NO.: 14114.0332U3 (MLM/WBD:tmh)

RECEIVED

MAR 1 4 2002

NEEDLE & ROSENBERG

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

| □ BLACK BORDERS □ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES □ FADED TEXT OR DRAWING □ BLURRED OR ILLEGIBLE TEXT OR DRAWING □ SKEWED/SLANTED IMAGES □ COLOR OR BLACK AND WHITE PHOTOGRAPHS □ GRAY SCALE DOCUMENTS | Defects in the images metade out are not immed to the items encoured. | | | | |
|--|---|--|--|--|--|
| ☐ FADED TEXT OR DRAWING ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING ☐ SKEWED/SLANTED IMAGES ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS | ☐ BLACK BORDERS | | | | |
| □ BLURRED OR ILLEGIBLE TEXT OR DRAWING □ SKEWED/SLANTED IMAGES □ COLOR OR BLACK AND WHITE PHOTOGRAPHS | \square image cut off at top, bottom or sides | | | | |
| ☐ SKEWED/SLANTED IMAGES ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS | ☐ FADED TEXT OR DRAWING | | | | |
| ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS | ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING | | | | |
| | ☐ SKEWED/SLANTED IMAGES | | | | |
| GRAY SCALE DOCUMENTS | ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS | | | | |
| | ☐ GRAY SCALE DOCUMENTS | | | | |
| LINES OR MARKS ON ORIGINAL DOCUMENT | LINES OR MARKS ON ORIGINAL DOCUMENT | | | | |
| ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY | ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY | | | | |
| | (-) (-) | | | | |

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.